Core Insights - Meta has appointed Shengjia Zhao, co-creator of OpenAI's ChatGPT, as the chief scientist of Meta Superintelligence Labs [1][3] - The company has made significant investments in artificial intelligence, including a $14 billion investment in Scale AI [2] - Meta Superintelligence Labs was established to bring together top AI researchers and engineers, with Zhao being a key figure from its inception [2][3] Investment and Hiring Strategy - Zuckerberg has been actively hiring AI talent, indicating a multibillion-dollar investment strategy in the AI sector [2] - The establishment of Meta Superintelligence Labs is part of a broader initiative to enhance the company's capabilities in artificial intelligence [2] Leadership and Vision - Shengjia Zhao is recognized for his pioneering work in AI, including a new scaling paradigm, and will collaborate closely with Zuckerberg and Alexandr Wang, Meta's chief AI officer [3][4] - Zuckerberg expressed enthusiasm about working with Zhao to further advance the scientific vision of the lab [4]

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/biohaven-ltd-lawsuit-sub ...

Forget meme stocks. These retail traders are tapping 500-to-1 leverage to make big, and dangerous, bets in currency markets.Read The Big Take ⬇️ https://t.co/HkjnInz8xx ...

Core Viewpoint - Carbon Revolution plc has secured a total of US$27 million in funding, which includes a US$5 million release from Orion Infrastructure Capital and US$400,000 from existing loan reserves, but has revised its revenue forecasts downward due to a decline in wheel orders and may need additional funding in the near future [1][2][3]. Funding Details - Orion Infrastructure Capital has released US$5 million of a previously announced US$25 million facility, completing the full release of this facility [1]. - Existing Noteholders have released the final US$400,000 of existing loan reserves, bringing the total reserves released to US$2 million [1]. - Both OIC and Existing Noteholders have agreed to partial payment in kind for certain interest payments for approximately six months [2]. Revenue Forecast and Expansion Plans - The company has experienced a decline in the volume of wheels ordered, leading to a downward revision of revenue forecasts and a slowdown in short-term expansion plans [3]. - Due to the decline in revenue and delays in customer payments, the company anticipates needing additional funding within the next quarter [3]. - Discussions are ongoing with OIC regarding potential additional funding, including access to remaining funds under the Securities Purchase Agreement [3]. Company Overview - Carbon Revolution plc is a leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, supplying to high-performance, premium, and luxury automotive brands [4]. - The company has transitioned from producing single prototypes to manufacturing lightweight wheels for various automotive segments [4]. - Carbon Revolution aims to create a sustainable advanced technology business in the automotive industry [4].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Nutex Health Inc. (“Nutex” or “the Company”) (NASDAQ: NUTX) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Nutex investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesl ...

He was lured into the military by a big sign-on bonus—and was stunned by what he found. A Russian soldier’s perspective on the war in Ukraine. https://t.co/xt82zl15rj ...

Core Insights - CVS Health and UnitedHealth have contrasting first-quarter results, with CVS showing strong growth and raising its full-year EPS guidance, while UnitedHealth missed earnings and revenue expectations, leading to a significant cut in its 2025 EPS outlook [1][19] Group 1: CVS Health Performance - CVS Health's Health Care Benefits segment reported an 8% year-over-year revenue growth in Q1, with medical membership stable at approximately 27.1 million [4] - The adjusted operating income for CVS Health surged to $1.99 billion from $732 million a year ago, driven by the strength in commercial insurance [4][8] - CVS's medical benefit ratio (MBR) improved to 87.3% from 90.4% year-over-year, aided by reserve releases and better Medicare Advantage star ratings [6] Group 2: UnitedHealth Challenges - UnitedHealth's medical care ratio (MCR) increased to 84.8%, up from 84.3% in 2024, due to elevated Medicare Advantage utilization, prompting a cut in 2025 adjusted earnings guidance to $26.00-$26.50 per share [10] - The company is facing significant cost pressures, particularly in outpatient and professional services, which are expected to continue affecting earnings throughout 2025 [10][19] - UnitedHealth's Optum segment saw a 14% year-over-year revenue increase, driven by rising script volumes and specialty pharmacy strength [9] Group 3: Valuation Comparison - CVS is trading at a forward P/E of 8.88X, below its 5-year median of 9.55X, while UnitedHealth is at 11.98X, also below its 5-year median of 19.20X, indicating that CVS is more attractively valued relative to UnitedHealth [16][17] - The Zacks Consensus Estimate for CVS's Q2 2025 EPS suggests a 19.7% decline year-over-year, while UnitedHealth's estimate implies a 28.8% decline [11][14] Group 4: Strategic Initiatives - CVS is conducting a strategic review of Oak Street Health, which it acquired for $10.6 billion, focusing on capital allocation towards higher-return investments [5] - Despite pressures in Medicare Advantage, CVS is positioned as a stronger investment option ahead of Q2 earnings due to its stable commercial insurance performance and disciplined capital management [19]

Core Viewpoint - Treatment.com AI Inc. is initiating a non-brokered private placement to raise up to C$3 million due to strong interest from investors, offering special warrants and units at C$0.50 each [1][5]. Group 1: Offering Details - The offering consists of special warrants and units, with each unit comprising one common share and one common share purchase warrant [1]. - Each warrant allows the holder to acquire one share at C$0.75 for 12 months following issuance [1]. - Special warrants will automatically convert into units on the earlier of the filing of a prospectus supplement or four months and one day after issuance [2]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized for working capital purposes [5]. Group 3: Conditions and Fees - The offering is expected to close by August 18, 2025, and is subject to necessary approvals, including from the Canadian Securities Exchange [5]. - The company may pay a finder's fee of up to 8% of gross proceeds and issue broker warrants equal to 8% of the number of special warrants and/or units sold [4]. Group 4: Company Overview - Treatment.com AI is focused on improving healthcare through AI and best clinical practices, with a comprehensive healthcare AI engine known as the Global Library of Medicine (GLM) [7]. - The GLM provides clinical information and support to healthcare professionals, helping to reduce administrative burdens and improve patient care [7].

Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States.Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; 939: FRA) is pleased to announce that due to strong inbound interest from new and existing investors, it is undertaking a non-brokered private placement of up to C$3 million of a com ...

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Luminar Technologies, Inc. (“Luminar” or “the Company”) (NASDAQ: LAZR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired L ...